Highbridge Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Highbridge Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-24,522	Closed	-$352K	–	1503
2017 Q2	$352K	Sell	24,522 -15,654	-39%	-$198K	0.01%	901
2017 Q1	$370K	Sell	40,176 -11,767	-23%	-$115K	0.01%	1044
2016 Q4	$541K	Buy	51,943 +30,357	+141%	+$261K	0.01%	740
2016 Q3	$195K	Buy	+21,586	New	+$183K	﹤0.01%	1184
2016 Q2	–	Sell	-17,837	Closed	-$161K	–	1358
2016 Q1	$161K	Buy	17,837 +4,006	+29%	+$32.5K	﹤0.01%	1374
2015 Q4	$179K	Sell	13,831 -49,185	-78%	-$502K	﹤0.01%	1370
2015 Q3	$609K	Buy	+63,016	New	+$578K	0.01%	963

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Highbridge Capital Management's AKBA Position: Q3 2017 in Review

Highbridge Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2017, closing a stake of 24,522 shares — an estimated $352K sold.

Highbridge Capital Management first reported a position in AKBA in Q3 2015 and held it in 7 quarters. The position peaked at $609K in Q3 2015. 119 funds tracked by Wall St. Rank hold AKBA as of Q3 2017.

Highbridge Capital Management reported no remaining Akebia Therapeutics position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 24,522 Akebia Therapeutics shares in Q3 2017, an estimated $352K.
Highbridge Capital Management first reported a position in Akebia Therapeutics in Q3 2015 and held it in 7 quarters.
Highbridge Capital Management's Akebia Therapeutics position peaked at $609K in Q3 2015.
119 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.